Sanofi trial shows Fluzone high-dose flu vaccine efficacy
PARIS (Reuters) - Sanofi said on Monday that a large clinical trial showed its Fluzone High-Dose vaccine to be more effective at preventing influenza in adults aged 65 and older than a standard dose of Fluzone.
Sanofi said it plans to submit the full clinical study report to the U.S. Food and Drug Administration for review by early 2014 and will seek to modify to the label for Fluzone High-Dose vaccine to reflect the superior efficacy data in this age group.
In the study, which included roughly 30,000 participants, Fluzone High-Dose vaccine was 24.2 percent more effective in preventing influenza in adults 65 years of age and older than Fluzone vaccine.
Fluzone High-Dose vaccine was licensed for sale by the FDA in 2009 under an accelerated approval process that included a requirement that Sanofi complete a large-scale confirmatory study.
(Reporting by Leila Abboud)
- Islamic State video claims to show beheading of U.S. journalist |
- Gaza war rages on, Hamas says Israel tried to kill its military chief |
- Four beheaded corpses found in Egypt's Sinai: security sources
- Father of Texas 'affluenza' teen arrested for impersonating police officer
- U.S. attorney general visits racially charged St. Louis suburb
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video